Angiotensin-converting enzyme (ACE) inhibitor therapy after myocardial infarction in relation to left ventricular function

Scandinavian Cardiovascular Journal

Volumn 37, Issue 3, 2003, Pages 130-134

  Reikvam, Aasmund ^a   Kvan, Elena ^a   Landmark, Knud ^a   Aursnes, Ivar ^a   Waage, K ^b   Vagan A M ^c   Hovland, A ^d   Anker, E ^e   Zalmai, A ^f   Haanaes O C ^g   Dahl, T ^h   Knutsen, K ⁱ   Platou, C ^j   Gronvold T ^k   Vandvik, P O ^l   Haerem J ^k   Dorum H P ^m   von der Lippe, A ⁿ   Pettersen, K ^o   Mangschau, A ^p  

^a UNIVERSITY OF OSLO   (Norway)

^b HAUGESUND HOSPITAL   (Norway)

^c Central Hospital of More/Romsdal   (Norway)

^d Central Hospital of Nordland   (Norway)

^e NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^f LOVISENBERG DIAKONALE HOSPITAL   (Norway)

^g Tynset County Hospital   (Norway)

^h AKER UNIVERSITY HOSPITAL   (Norway)

ⁱ Vestfold Central Hospital   (Norway)

^j Innherred Hospital   (Norway)

^k Medical Department   (Norway)

^l Oppland Central Hospital   (Norway)

^m Oppland County   (Norway)

ⁿ DIAKONHJEMMET HOSPITAL   (Norway)

^o AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^p ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Cardiovascular drugs; Heart failure; Myocardial infarction; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING DRUG; NITRATE; TICLOPIDINE;

ACUTE HEART INFARCTION; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; DRUG INDICATION; DRUG USE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; SECONDARY PREVENTION;

EID: 0037924394     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430310005821     Document Type: Article

References (18)

1. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
2. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
3. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-677.
4. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence on heart failure. Lancet 1993; 342: 821-828.
5. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
6. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1121.
7. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
8. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
9. Reikvam Å, Kvan E, Aursnes I, for the INPHARM Study Investigators. Use of cardiovascular drugs after myocardial infarction: A marked shift towards evidence-based drug therapy. Cardiovasc Drugs Ther 2002; 16: 451-456.
10. The European Secondary Prevention Study Group. Translation of clinical trials into practice: A European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996; 347: 1203-1207.
11. Reikvam Å, Aursnes I. Hospital mortality from acute myocardial infarction has been modestly reduced after introduction of thrombolytics and aspirin: Results from a new analytical approach. J Clin Epidemiol 1999; 52: 609-613.
12. Gardner MJ, Altman DG. Statistics with confidence. London: British Medical Journal 1989.
13. van't Hof AW, Schipper CW, Gerritsen JG, et al. Comparison of radionuclide angiography with three echocardiographic parameters of left ventricular function in patients after myocardial infarction. Int J Card Imaging 1998; 14: 413-418.
14. Jensen-Urstad K, Bouvier F, Hojer J, et al. Comparison of different echocardiographic methods with radionuclide imaging for measuring left ventricular fraction during acute myocardial infarction treated by thrombolytic therapy. Am J Cardiol 1998; 81: 538-544.
15. Hole T, Otterstad JE, St John Sutton M, et al. Differences between echocardiographic measurements of left ventricular dimensions and function by local investigators and a core laboratory in a 2-year follow-up study of patients with an acute myocardial infarction. Eur J Echocardiogr 2002; 3: 263-270.
16. Smith SC, Blair S, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001; 104: 1577-1579.
17. Fox KM, Henderson JR, Bertrand ME, et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998 Sep; 19 Suppl J: J52-J55.
18. Pfeffer MA, Domanski M, Rosenberg Y, et al. Prevention of events with angiotensin-converting enzyme inhibitors (the PEACE Study design). Am J Cardiol 1998; 82: 25H-30H.